Business Description
Hyloris Pharmaceuticals SA
ISIN : BE0974363955
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 17.37 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.12 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 8.41 | |||||
Beneish M-Score | -2.17 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 110.9 | |||||
3-Year EBITDA Growth Rate | -28 | |||||
3-Year EPS without NRI Growth Rate | -17.8 | |||||
3-Year FCF Growth Rate | -26.7 | |||||
3-Year Book Growth Rate | -15.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 160.77 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 44.28 | |||||
9-Day RSI | 45.64 | |||||
14-Day RSI | 43.52 | |||||
6-1 Month Momentum % | -44.62 | |||||
12-1 Month Momentum % | -50.24 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.22 | |||||
Quick Ratio | 5.22 | |||||
Cash Ratio | 4.5 | |||||
Days Sales Outstanding | 713.15 | |||||
Days Payable | 11550.48 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.7 | |||||
Shareholder Yield % | -0.78 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 95.54 | |||||
Operating Margin % | -759.27 | |||||
Net Margin % | -736.94 | |||||
FCF Margin % | -649.64 | |||||
ROE % | -32.56 | |||||
ROA % | -27.85 | |||||
ROIC % | -102.21 | |||||
3-Year ROIIC % | -80.31 | |||||
ROC (Joel Greenblatt) % | -784.04 | |||||
ROCE % | -31.4 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 76.76 | |||||
PB Ratio | 4.07 | |||||
Price-to-Tangible-Book | 4.51 | |||||
EV-to-EBIT | -8.51 | |||||
EV-to-EBITDA | -8.7 | |||||
EV-to-Revenue | 62.48 | |||||
EV-to-FCF | -9.62 | |||||
Price-to-Net-Current-Asset-Value | 5.98 | |||||
Price-to-Net-Cash | 7.28 | |||||
Earnings Yield (Greenblatt) % | -11.75 | |||||
FCF Yield % | -8.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Hyloris Pharmaceuticals SA Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 2.087 | ||
EPS (TTM) (€) | -0.549 | ||
Beta | 0.85 | ||
Volatility % | 52.87 | ||
14-Day RSI | 43.52 | ||
14-Day ATR (€) | 0.431141 | ||
20-Day SMA (€) | 5.7515 | ||
12-1 Month Momentum % | -50.24 | ||
52-Week Range (€) | 2.89 - 14.1 | ||
Shares Outstanding (Mil) | 28 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Hyloris Pharmaceuticals SA Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Hyloris Pharmaceuticals SA Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Hyloris Pharmaceuticals SA Frequently Asked Questions
What is Hyloris Pharmaceuticals SA(XBRU:HYL)'s stock price today?
When is next earnings date of Hyloris Pharmaceuticals SA(XBRU:HYL)?
Does Hyloris Pharmaceuticals SA(XBRU:HYL) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |